Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hau

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Neuro-Oncology|May 9, 2026
ClpP Activation in High-Risk Medulloblastoma: ONC206 as a Potent Inducer of the Integrated Stress Response and Mitochondrial Damage for a Broader Therapeutic WindowPeter Hau
Neuro-Oncology|June 17, 2021
Dissecting adult SHH-activated medulloblastoma-molecularly defined tumor subsets reveal new prognostic biomarkersPeter Hau
International Journal of Molecular Sciences|September 19, 2018
Drug Repurposing of Metabolic Agents in Malignant GliomaCorinna Seliger, Peter Hau
Case Reports in Oncology|August 2, 2013
High-grade glioma: refined diagnostics steering stratified therapyMartin Uhl, Peter Hau
Neuro-Oncology Practice|July 15, 2024
Platform trials for rare cancers-A complex innovation to accelerate knowledgePeter Hau, Michael C Frühwald
Pathology Oncology Research : POR|April 1, 2005
ROC analysis as an additional method to characterize time to event dataHorst J Koch, Peter Hau
Current Medicinal Chemistry|June 10, 2008
Procarbazine--a traditional drug in the treatment of malignant gliomasRainer Goerne, Ulrich Bogdahn, Peter Hau
Expert Review of Anticancer Therapy|November 10, 2009
Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotidesPeter Hau, Piotr Jachimczak, Ulrich Bogdahn
Disease Markers|February 28, 2007
MGMT methylation status: the advent of stratified therapy in glioblastoma?Peter Hau, Roger Stupp, Monika E Hegi
Current Pharmaceutical Biotechnology|May 31, 2011
TGF-β2 signaling in high-grade gliomasPeter Hau, Piotr Jachimczak, Jürgen Schlaier, et al.
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Neuro-Oncology|May 9, 2026
ClpP Activation in High-Risk Medulloblastoma: ONC206 as a Potent Inducer of the Integrated Stress Response and Mitochondrial Damage for a Broader Therapeutic WindowPeter Hau
Neuro-Oncology|June 17, 2021
Dissecting adult SHH-activated medulloblastoma-molecularly defined tumor subsets reveal new prognostic biomarkersPeter Hau
International Journal of Molecular Sciences|September 19, 2018
Drug Repurposing of Metabolic Agents in Malignant GliomaCorinna Seliger, Peter Hau
Case Reports in Oncology|August 2, 2013
High-grade glioma: refined diagnostics steering stratified therapyMartin Uhl, Peter Hau
Neuro-Oncology Practice|July 15, 2024
Platform trials for rare cancers-A complex innovation to accelerate knowledgePeter Hau, Michael C Frühwald
Pathology Oncology Research : POR|April 1, 2005
ROC analysis as an additional method to characterize time to event dataHorst J Koch, Peter Hau
Current Medicinal Chemistry|June 10, 2008
Procarbazine--a traditional drug in the treatment of malignant gliomasRainer Goerne, Ulrich Bogdahn, Peter Hau
Expert Review of Anticancer Therapy|November 10, 2009
Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotidesPeter Hau, Piotr Jachimczak, Ulrich Bogdahn
Disease Markers|February 28, 2007
MGMT methylation status: the advent of stratified therapy in glioblastoma?Peter Hau, Roger Stupp, Monika E Hegi
Current Pharmaceutical Biotechnology|May 31, 2011
TGF-β2 signaling in high-grade gliomasPeter Hau, Piotr Jachimczak, Jürgen Schlaier, et al.
Pageof 18